BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cladribine (MAVENCLAD®) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cladribine (MAVENCLAD®)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04178005-7191@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Cladribine (MAVENCLAD®): Phase 4 readout est. (NCT04178005)
DESCRIPTION:Cladribine (MAVENCLAD®)\, phase 4\, Multiple Sclerosis.\nStudy
 : Cladribine Tablets After Treatment With Natalizumab (CLADRINA)\nEstimate
 d primary completion: 30 May 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cladribine-mavenclad#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04178005
URL:https://assetmemo.bio/drug/cladribine-mavenclad#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04695080-7191@assetmemo.bio
DTSTAMP:20261121T005016Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cladribine (MAVENCLAD®): Phase 2/3 readout est. (NCT04695080)
DESCRIPTION:Cladribine (MAVENCLAD®)\, phase 2/3\, Multiple Sclerosis.\nStu
 dy: ChariotMS - Cladribine to Halt Deterioration in People With Advanced M
 ultiple Sclerosis\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cladribine-mavenclad#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04695080
URL:https://assetmemo.bio/drug/cladribine-mavenclad#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
